Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
Go back to Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia| ARROWHEAD RESEARCH (NASDAQ: ARWR) | Delayed: 86.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $86.34 | 52 Week High | $8.22 | |||
| Open | $86.34 | 52 Week Low | $3.07 | |||
| Day High | $86.34 | P/E | N/A | |||
| Day Low | $86.34 | EPS | $-1.30 | |||
| Volume | 7,142 | |||||
